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Background: Melanoma antigen D1 (MAGED1) is a member of the type II melanoma antigen (MAGE) family. The
down-regulation of MAGED1 expression has been shown in breast carcinoma cell lines and in glioma stem cells
and may play an important role in apoptosis and anti-tumorigenesis. However, there is no report on its clinical role
in colorectal cancer (CRC).
Methods: We examined the expression of MAGED1 by qPCR in colorectal cancer tissues and their adjacent non-
tumorous tissues taken from 6 cases and performed Western blotting and IHC analyses. In addition, we analyzed
MAGED1 expression in 285 clinicopathologically characterized colorectal cancer patients.
Results: MAGED1 expression was significantly down-regulated in colorectal cancer tissues compared with adjacent
non-tumorous tissues and was associated with clinical stage (p< 0.001), T classification (p= 0.001), N classification
(p< 0.001), M classification (p< 0.001) and pathologic differentiation (p= 0.002). Patients with lower MAGED1
expression had a shorter survival time than those with higher MAGED1 expression. Univariate and multivariate
analyses indicated that MAGED1 expression was an independent prognostic factors (p< 0.001).
Conclusions: MAGED1 may serve as a novel prognostic biomarker of human colorectal cancer.
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The melanoma antigen (MAGE) family, which includes
more than 25 members, is classified into two subfamilies
based on the structural differences of the genes and tissue-
specific gene expressions. Type I MAGE genes are classic-
ally subdivided into three clusters (MAGE-A, B, and C),
which are expressed in a variety of cancer cells, but are sel-
dom expressed in normal cells [1-4]. Type II MAGE genes
include MAGE-D (MAGED1 to MAGED14), MAGEE1 to
H1, MAGEL2 and NECDIN [5]. In contrast to type I
MAGE genes, type II MAGE genes are expressed in a var-
iety of normal tissues and cell lines [6,7].
Melanoma antigen D1 (MAGED1), also known as
Dlxin-1 or NRAGE, is a member of the type II MAGE* Correspondence: xurh@sysucc.org.cn
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reproduction in any medium, provided the orfamily. It was reported that MAGED1 modulated the
transcriptional activity of DLx5/Msx2, regulating osteo-
blast differentiation during development [8,9]. Unlike
the type I MAGE genes, which encode tumor antigens,
MAGED1 encodes a protein involved in the apoptosis
pathway. MAGED1 mediates cellular apoptosis and cell
cycle arrest through the c-JNK and p53-dependent path-
ways [10-12], and is also involved in the BRCA2-
mediated cell proliferation arrest in a p53-independent
manner [13].
In addition to normal tissue expression, type II MAGE
genes, including MAGED1, were also detected in cancer
cells. It was reported that the expression of MAGED1 was
down-regulated in breast carcinoma cell lines [13] and in
glioma stem cells [14]. Chung et al. examined the expres-
sion profile of MAGE family genes in Taiwanese patients
with colorectal cancer and discovered that the type II
MAGE genes MAGED12, MAGEF1, and MAGEH1 are
frequently up-regulated in tumors [15].td. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Table 1 Clinical data of 285 samples of colorectal cancer





≤ 50 111 (38.9)


























Non-mucinous adenocarcinoma 268 (94.0)
mucinous adenocarcinoma 17 (6.0)
Vital status (at follow-up)
Alive 173 (60.7)
Death (All colorectal cancer-related) 112 (39.3)
Expression of MAGED1-1
Low expression 161 (56.5)
High expression 124 (43.5)
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apoptosis and anti-tumorigenesis, there are no reports
on its clinical role in colorectal cancer. In this study, we
investigated MAGED1 expression and its clinical signifi-
cance in human colorectal cancer. We found that
MAGED1 expression was significantly down-regulated
in colorectal cancer tissues compared with their adjacent
non-tumorous tissues (ANT) and was associated with
the clinical features of colorectal cancer. MAGED1 may
serve as a novel prognostic biomarker of human colorec-
tal cancer.
Methods
Patient information and tissue specimens
This study was conducted on a total of 285 paraffin-em-
bedded, archived CRC primary samples, which were
histopathologically and clinically diagnosed at the Sun
Yat-sen University Cancer Center from 1999 to 2007.
The clinical and clinicopathological classification and
stage were determined according to the American Joint
Committee on Cancer (AJCC) TNM staging system.
Each lesion was graded histologically according to the
WHO classification criteria. Overall survival (OS) was
defined as the interval between the date of surgery and
date of death or the last known follow up. For the use of
these clinical materials for research purposes, prior con-
sent of the patients and approval from the Institutional
Research Ethics Committee were obtained. Six pairs of
colorectal cancer tissue specimens and corresponding
adjacent non-tumorous specimens were obtained from
patients with CRC who underwent surgical CRC tissue
resection at Sun Yat-sen University Cancer Center. Writ-
ten informed consent was obtained from each patient
before surgery. All excised samples were obtained within
1 h after the operation from tumor tissues and corre-
sponding adjacent non-tumorous specimens 5–10 cm
from the tumor. For all excised tissues, half of each spe-
cimen was placed into liquid nitrogen until further ana-
lysis and the remainder was fixed by formalin processed
for immunohistochemistry (IHC). The clinical informa-
tion related to the 285 CRC samples is described in de-
tail in Table 1.
RNA extraction, reverse transcription and real-time PCR
Total RNAs from 6 pairs of tumor tissues and non-
tumorous tissues was extracted using Trizol reagent (Invi-
trogen, Carlsbad, California, USA) according to the manu-
facturer’s instructions. First-strand cDNA was synthesized
by reverse transcriptase (Invitrogen, Carlsbad, California,
USA) using total RNA as a template. Real-time PCR was
carried out using an ABI Prism 7500 Sequence Detection
System (Applied Biosystems, Foster City, California, USA).
The sequences of the primers were as follows: MAGED1:
sense primer, 50 GATTCCCTCAGACCTTTGC; anti-senseprimer, 50 GAAGGAATCTGAGGCTTCAG; 18S was
amplified as an internal control using the following pri-
mers: sense primer, 50 CCTGGATACCGCAGCTAGGA;
anti-sense primer, 50 GCGGCGCAATACGAATGCCCC.
Real-time PCR was performed using programmed para-
meters for the SYBR Green method (Invitrogen, Carlsbad,
California, USA) to collect the fluorescent signals, heating
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and 72°C for 32 s for 40 cycles. All gene expression values
were normalized using the housekeeping gene 18S and cal-
culated using the comparative CT method (ΔΔCT method).
Western blotting
Western blotting was performed according to standard
methods as described previously [16]. MAGED1 expres-
sion was determined with anti-rabbit immunoglobulin G
(1:2,000; Abcam, Cambridge, MA) according to the manu-
facturer’s suggested protocols. An anti-αtubulin mouse
monoclonal antibody (1:2,000; Boster, Wuhan, China) was
used as the loading control.
Immunohistochemistry (IHC)
Immunohistochemistry was performed to study altered
protein expression in 285 human colorectal cancer tissues.
IHC was carried out according to standard methods as
described previously [16]. Briefly, the tissue sections were
deparaffinized in xylene at 37°C for 20 min and rehy-
drated. Endogenous peroxide was blocked by incubating
the sections with 3% hydrogen peroxide in methanol for
20 min at 37°C. The sections were then submerged in
10 mM citrate buffer (pH 6.0) and microwaved for anti-
genic retrieval, followed by incubation with rabbit anti-Figure 1 Decreased expression of MAGED1-1 in colorectal cancer. A,
mRNA expression in each of the primary colon cancer tissues (T) and adjacen
Western blotting (B) and IHC (C) analyses of MAGED1-1 protein in each of the
tissues (ANT) paired from the same patient.MAGED1 (1:200; Millipore, Billerica, MA) overnight at
4°C. After washing, tissue sections were treated with
anti-rabbit secondary antibody for 30 min, followed by
further incubation with streptavidin horseradish peroxid-
ase complex. The sections were developed with diamino-
benzidine tetrahydrochloride (DAB) and counterstained
with hematoxylin.
The proportion of the stained cells and the extent of
the staining were used as criteria of evaluation. Slides
were scored by two independent observers who were
blinded to the patient data. For each case, at least 1,000
tumor cells were analyzed, and the percentage of posi-
tively stained tumor cells was recorded. For each sample,
the proportion of MAGED1-expressing cells varied from
0% to 100%, and the intensity of staining varied from
weak to strong. One score was given according to the
percent of positive cells as follows: ≤ 10%= 0, >10% to ≤
25%= 1, >25% to ≤ 50%= 2, >50% to≤ 75%= 3, >75%= 4.
Another score was given according to the intensity of
staining as negative = 0, weak = 1, moderate = 2, or
strong = 3. A final score was then calculated by multiply-
ing the two above scores. If the final score was equal to
or less than four, the tumor was considered as having
low expression; otherwise, the tumor was considered as
having high expression.Real time RT-PCR analysis of the normal/tumor ratio of MAGED1-1
t non-cancerous colon tissues (ANT) paired from the same patient. B-C,
primary colon cancer tissues (T) and adjacent non-cancerous colon
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All statistical analyses were performed using by the SPSS
16.0 statistical software package (SPSS Inc., Chicago, IL).
The relationship between MAGED1 expression and the
clinicopathologic characteristics was analyzed by the χ2
test. Survival curves were plotted by the Kaplan-Meier
method and compared using the log-rank test. Survival
data were evaluated using univariate and multivariate
Cox regression analyses. A p-value of less than 0.05 was
considered statistically significant in all cases.
Results
MAGED1 expression in paired colorectal cancer and
non-tumorous tissues
Real-time PCR, western blotting and IHC analysis
showed that MAGED1 mRNA and protein expression
were significantly down-regulated in all six pairs of
human colorectal cancer tissues compared with matched
adjacent non-tumorous tissues (Figure 1A-C) Additional
file 1: Table S1.
131 colorectal cancer and matched ANT samples
derived from the 285 archival primary colorectal cancer
tissues were evaluated MAGED1 protein expression by
IHC analysis Additional file 2: Table S2. We defined the
scores less than or equal to four, including non-
expression as low MAGED1 expression referring to their









Clinical Stage I + II
III
IV









Histological Types Non-mucinous adenocarcinoma
mucinous adenocarcinomasamples, otherwise, they were considered as having high
MAGED1 expression. According to the definition, the
rate of low MAGED1 expression (74/131, 56.5%) in
colorectal cancer samples significantly differed from the
rate in matched ANT samples (13/131, 10.0%)
(p = 0.031). Furthermore, MAGED1 expression was
down-regulated in 58.8% (77/131) and up-regulated only
in 22.1% (29/131) colorectal cancer tissues, compared
with their paired ANT tissues according to the scoring
system. These results suggest that MAGED1 expression
is down-regulated in colorectal cancer tissues.Correlation between MAGED1 protein expression and
clinicopathological features
MAGED1 protein expression was evaluated by immuno-
histochemistry in 285 paraffin-embedded, archival pri-
mary colorectal cancer tissues. The samples included 47
cases of clinical stage I (16.5%), 61 cases of stage II
(21.4%), 88 cases of stage III (30.9%) and 89 cases of
stage IV (31.2%) colorectal cancer. MAGED1 protein
was detected in 261 of 285 CRC cases (91.6%), but in
only 5 of 17 colorectal mucinous adenocarcinoma cases
(29.4%). According to the scoring system, low MAGED1
expression was detected in 161/285 (56.5%) colorectal
carcinomas, while the high MAGED1 expression was
detected in 124/285 (43.5%).opathological characteristics of colorectal cancer patients
MAGED1-1 Chi-square test P-value
one No. cases (%) High No. cases (%)
63 (39.1) 39 (31.5) 0.213
98 (60.9) 85 (68.5)
65 (40.4) 46 (37.1) 0.625
96 (59.6) 78 (62.9)
70 (43.5) 63 (50.8) 0.233
91 (56.5) 61 (49.2)
35 (21.7) 73 (58.9) <0.001
60 (68.2) 28 (31.8)
66(74.2) 23(25.8)
24 (14.9) 40 (32.3) 0.001
137 (85.1) 84 (67.4)
43 (26.7) 80 (64.5) <0.001
118 (73.3) 44 (35.5)
95 (59.0) 101 (81.5) <0.001
66 (41.0) 23 (18.5)
44 (27.3) 14 (11.3) 0.002
108 (67.1) 97 (78.2)
9 (5.6) 13 (10.5)
148 (92.5) 120 (96.0) 0.227
12 (7.5) 5(4.0)
Figure 2 Decreased expression of MAGED1-1 in advanced colorectal cancer. Representative IHC analyses of MAGED1-1 expression in normal
colorectal tissues and colorectal cancer specimens of different clinical stages (left column). The examples of the scoring system for different
scores were also showed (right column).
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MAGED1 expression and clinical characteristics was
analyzed in 285 CRC cases. There was no significant
correlation between MAGED1 protein expression and
gender, age, tumor location, or histological types of
CRC. However, MAGED1 expression was closely asso-
ciated with clinical stage (p < 0.001), T classification
(p= 0.001), N classification (p < 0.001), M classification
(p < 0.001) and pathologic differentiation (p= 0.002).
The MAGED1 protein expression was inversely corre-
lated with clinical stage and T classification. Higher sta-
ging and poor pathological differentiation were
correlated with lower MAGED1 expression (Figures 2
and 3). In addition, most of the colorectal mucinous
adenocarcinoma cases (12/17) were demonstrated low
MAGED1 expression.
Survival analysis
A Kaplan-Meier analysis and the log-rank test were used
to calculate the effects of the clinicopathologicalcharacteristics and MAGED1 expression on survival.
The expression of MAGED1 in colorectal cancer was
significantly correlated with patients’ survival time (p
<0.001). Patients with lower MAGED1 expression had a
shorter overall survival time (OS) than those with higher
MAGED1 expression (median OS 47 months vs has not
been reached, respectively; p < 0.001). The overall two-,
three-, and five-year accumulative survival rates were
68.8%, 57.2%, and 46.1%, respectively, in cases with low
MAGED1 expression and were 93.5%, 80.2%, and 78.4%,
respectively, in cases with high level of MAGED1 ex-
pression(Figure 4A). Additionally, similar results were
obtained in stage III and IV subgroup patients
(Figure 4C), but stage I-II subgroup patients did not
show the similar results (Figure 4B).
Furthermore, univariate and multivariate analyses indi-
cated that clinical stage, pathologic differentiation, and
MAGED1 expression were independent prognostic fac-
tors (Table 3), suggesting that MAGED1 may be a prog-
nostic factor for survival in colorectal cancer patients.
Figure 3 MAGED1-1 expression in colorectal cancer tissues with
different pathologic differentiation.
Figure 4 Kaplan-Meier curves with univariate analyses (log-rank) for p
MAGED1-1 expression tumors (bold line). A, The overall survival of patie
overall survival of patients (clinical stages I-II) with low/high MAGED1-1 exp
low/high MAGED1-1 expression.
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In the present study, we demonstrated that MAGED1 ex-
pression was down-regulated at both the mRNA and pro-
tein levels in colorectal cancer tissues compared to
matched adjacent non-tumorous tissues. Low levels of
MAGED1 expression were more frequently observed in
CRC patients with poor pathologic differentiation or those
with advanced stages. This is the first study to analyze the
prognostic relevance of the MAGED1 expression in colo-
rectal carcinoma. We demonstrated that high MAGED1
expression was correlated with a better survival outcome,
whereas low MAGED1 expression was correlated with a
poorer survival outcome. Furthermore, MAGED1 expres-
sion was an independent prognostic factor, suggesting that
MAGED1 may be a prognostic factor for survival in colo-
rectal cancer patients.
MAGED1 expression may also be associated with the
histological types in CRC. We found that MAGED1 ex-
pression was low in most of the mucinous adenocarcin-
omas of CRC (12/17). Conversely, the rate of low
MAGED1 expression (148/268) in non-mucinous adeno-
carcinoma did not significantly differ from the rate of
high expression (120/268). However, because we could
only obtain a small number of mucinousatients with low MAGED1-1 expression (dotted line) versus high
nts (clinical stages I-IV) with low/high MAGED1-1 expression. B, The
ression. C, The overall survival of patients (clinical stages III and IV) with
Table 3 Univariate and multivariate analysis of various
prognostic parameters in patients with colorectal cancer
Cox-regression analysis
Variables Univariate analysis Multivariate analysis
No. P value Hazard Ratio 95% CI P value
MAGED1-1 <0.001 0.473 0.305-0.734 0.001
low expression 161
high expression 124
Age 0.388 1.006 0.992-1.020 0.419
≤ 50 111
> 50 174
Gender 0.555 1.048 0.706-1.555 0.817
Male 183
Female 102
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strate a significant correlation between the MAGED1 ex-
pression and the histological types in CRC (p= 0.227).
The inclusion of a greater number of mucinous adeno-
carcinoma samples may resolve the problem.
We also failed to observe a significant relationship be-
tween the MAGED1 expression and CRC patients’ survival
in the clinical stages I ~ II. We believe that this is due to
the good prognosis of the early stage CRC patients and
limit number of the clinical cases. However, there were sig-
nificant correlations between the MAGED1 expression and
overall survival in all patients and in clinical stage III and
IV patients.
MAGED1 expression was also evaluated by Chung et al.
in Taiwanese CRC patients, and reported MAGED1 over-
expression occurred in 45% CRC patients [15]. In the
present study, 131 CRC patients were enrolled to compare
their MAGED1 expression between colorectal cancer tis-
sues and paired adjacent non-tumorous tissues. The
MAGED1 expression was down-regulated in 58.8% (77/
131) and up-regulated only in 22.1% (29/131) CRC
patients. Compared the patients’ clinical characteristics in
these two studies, we found that the stage IV patients were
6.0% (6/100) vs 26.0% (34/131) in Chung et al.’s and our
study, respectively. Importantly, the present study has
shown that higher staging was correlated with lower
MAGED1 expression. Thus, we deduce that the lower
MAGED1 overexpression rate in our study was mostprobably because of the different distribution of clinical
stages in patients. On the other hand, different research
designs were performed in these two projects. Chung
et al.’s study was detected MAGED1 expression on gene
level; whereas our research was focus on its expression on
protein level, which post-translational modifications may
be involved in the expression regulation.
Different from the MAGED1, MAGED12 was reported
frequently up-regulated in tumors [15,17]. It was reported
that MAGED1 and -D2 RNA had different distribution
during the embryonic development and brain development
[18]. All these data suggested that different types of MAGE
genes may play distinct roles in biochemical activities.
A circadian rhythm is an approximate 24-h period in
the biological process of living entities, controlled by en-
dogenous clock genes [19,20]. Clock genes include
period (per), clock (clk), Bmal1, Rev-erb α, cryptochrome
(cry), and others [21]. MAGED1 was reported to regulate
the expression of Bmal1, Rev-erb α, and E4bp4 by bind-
ing to the RORα protein. The depletion of MAGED1
in vivo has been shown to cause severely dampened
oscillations of Bmal1 mRNA expression, resulting in an
increased the clock speed [22].
Mounting evidence shows that circadian disruption
increases cancer incidence and the cancer growth rate,
suggesting that circadian genes participate in the growth
and development of various cancers. Per2-deficient mice
showed a marked increase in tumor development and
reduced apoptosis in thymocytes following γ-radiation
[23]. Alternatively, overexpression of Per2 inhibited
tumor proliferation in vitro [24] and in vivo [25]. Other
clock genes, such as Bmal1, Clock, Cry and Rev-erbα,
have also been correlated with cancer [26-29]. In the
present study, we demonstrated that MAGED1 also has
a close relationship with the clinical features of colorec-
tal cancer, with higher MAGED1 expression in CRC
patients correlating with better survival and vice versa.
Because MAGED1 regulates Bmal1 and Rev-erb α ex-
pression and dampens the oscillations of Bmal1 expres-
sion, MAGED1 depletion can induce circadian rhythm
disorders [22]. We hypothesize that this may be the
mechanism by which MAGED1 expression correlates
with the CRC patients’ clinical features. However, the
precise mechanism of the MAGED1 involvement in
CRC development is still unclear. Thus, the further
study including overexpression and knockdown of
MAGED1 expression in CRC cells will be needed to ex-
plore the mechanism by which MAGED1 is involved in
the development and progression of colorectal cancer
and its exact regulating pathway in vitro and in vivo.
Conclusion
In the present study, we found that MAGED1 expres-
sion was significantly down-regulated in colorectal
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tissues and was associated with clinical stage, T classifi-
cation, N classification, M classification and pathologic
differentiation. MAGED1 expression was significantly
correlated with overall survival in colorectal cancer
patients. Patients with lower MAGED1 expression had a
shorter survival time than those with higher MAGED1
expression. MAGED1 may serve as a novel prognostic
biomarker of human colorectal cancer.
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Additional file 2: Table S2. Clinical data of 131 CRC patients compared
their MAGED1 expression between the colorectal cancer tissues and the
paired adjacent normal tissues.
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